<DOC>
	<DOCNO>NCT01026662</DOCNO>
	<brief_summary>This study : Evaluate vivo effect treatment eMatrixCO2 determine dynamic development time follow treatment .</brief_summary>
	<brief_title>In-vivo Analysis Fractional CO2 Laser System ( eMatrixCO2 ) Intended Treatment Soft Tissue</brief_title>
	<detailed_description />
	<criteria>Informed consent agreement sign subject . Healthy male female older 21 60 year age . Fitzpatrick skin type IV ( Although system clear skin type IVI , recommend use Matrix applicator skin type I V ) . Willingness follow treatment followup schedule posttreatment care . For female candidate postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment entire course study ( i.e. , oral contraceptive , IUD , contraceptive implant , barrier method spermicide , abstinence ) . Pregnant and/or breastfeeding . Having history disease stimulate heat , recurrent Herpes Simplex treat area , unless treatment conduct follow prophylactic regimen . Use nonsteroidal antiinflammatory drug ( NSAIDS , e.g. , ibuprofencontaining agent ) one week treatment session . Use retinoids , antioxidant therapeutic skin nourish supplement medicinal concentration within 2 month treatment study oral retinoids within 6 month study . Having receive treatment light , RF device treat area within 6 month treatment study . Having receive collagen/fat injection method augmentation inject implanted material treat area within 9 month treatment study . Having receive Botox treat area within 6 month treatment study . Having undergone surgery treat area within 6 month treatment ( skin heal completely ) study . History keloid scar abnormal wound healing . Suffering current history significant skin condition treat area inflammatory skin condition , include , limited : active acne , excessive skin dryness , psoriasis , eczema , rash , rosacea ( particularly severe open wound stage ) , varicella scar , open laceration abrasion active cold sore herpes sore prior treatment ( duration resolution per Investigator 's discretion ) treatment course . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication . History epidermal dermal disorder ( particularly involve collagen microvascularity ) . History pigmentary disorder , particularly tendency hyper hypopigmentation . Suffering hormonal imbalance , per Investigator 's discretion . Having know anticoagulative thromboembolic condition take anticoagulation medication one week prior treatment course ( allow inclusion , temporary cessation use per subject 's physician discretion ) . Having undergoing form treatment active cancer , history skin cancer cancer area treat , include actinic keratosis , presence malignant premalignant pigment lesion . Suffering significant concurrent illness , cardiac disorder , diabetes ( type I II ) , pertinent neurological disorder . Vascular lesion , tattoo permanent makeup treat area . Excessively tanned area treat unable/unlikely refrain tan study . Participation study another device drug within three month prior enrollment study . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Aesthetic dermatology</keyword>
</DOC>